Cancer Screening for Colorectal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether screening tests, such as flexible sigmoidoscopy (a procedure that examines the lower part of the large intestine), can help doctors detect colorectal cancer early and improve treatment outcomes. The goal is to determine if these screenings can reduce deaths from colorectal cancer. The trial includes two groups: one receives colorectal screenings, and the other receives standard medical care. This trial may suit individuals who have not undergone a colonoscopy or similar procedures in the last three years and are not currently receiving cancer treatment. As an unphased trial, it offers participants the chance to contribute to important research that could enhance early cancer detection and potentially save lives.
Do I need to stop my current medications for this trial?
The trial does not require you to stop taking your current medications. However, if you are a male who has taken Proscar/Propecia/finasteride in the past 6 months, you cannot join the trial. If you are already in the trial and your doctor prescribes finasteride, you can continue taking it.
What prior data suggests that sigmoidoscopy is safe for colorectal cancer screening?
Research has shown that flexible sigmoidoscopy, a test for colorectal cancer, is generally safe for most people. In a study of 112 individuals who underwent a similar test called a colonoscopy, 98% of the procedures were completed successfully, indicating that most people handle the procedure well.
Sigmoidoscopy has been proven to reduce the risk of developing and dying from colorectal cancer, demonstrating its effectiveness and general safety.
In summary, while all medical procedures carry some risk, sigmoidoscopy is considered a safe and effective method for colorectal cancer screening.12345Why are researchers excited about this trial?
Researchers are excited about the use of sigmoidoscopy for colorectal cancer screening because it offers a less invasive method compared to the full colonoscopy typically used as the standard of care. Unlike a colonoscopy, which examines the entire colon, a sigmoidoscopy focuses only on the lower part of the colon. This makes the procedure quicker and may require less preparation, potentially increasing patient comfort and compliance. Additionally, by performing screenings at baseline and again at year 5, researchers aim to gather valuable data on the long-term effectiveness of this approach in early detection of colorectal cancer.
What evidence suggests that sigmoidoscopy is effective for colorectal cancer screening?
Research has shown that flexible sigmoidoscopy, a method for checking colorectal cancer, effectively reduces both the number of cancer cases and deaths from the disease. In this trial, participants in the "Colorectal Screening" arm will undergo flexible sigmoidoscopy at baseline and year 5. One study found a 21% drop in colorectal cancer cases among screened individuals. Another study demonstrated that this screening method lowered the risk of developing cancer in different parts of the colon. Additionally, a simulation study highlighted a 7% reduction in colorectal cancer with sigmoidoscopy screening. These findings suggest that flexible sigmoidoscopy can significantly aid in the early detection and prevention of colorectal cancer.34567
Who Is on the Research Team?
Christine D Berg
Principal Investigator
National Cancer Institute (NCI)
Are You a Good Fit for This Trial?
This trial is for men and women aged 55 to 74 who haven't had certain cancer screenings in the past three years. It's not for those with a history of specific cancers, major organ removals, or current cancer treatment (except some skin cancers). Women who've had both ovaries removed could join after October 1996.Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Colorectal Screening
Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5
Follow-up
Participants are monitored for colorectal cancer incidence and mortality for at least 13 years
What Are the Treatments Tested in This Trial?
Interventions
- Sigmoidoscopy
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor